Media coverage about Aceto (NASDAQ:ACET) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aceto earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.1616302878076 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern’s scoring:
- Analyzing Aceto (ACET) and Celgene (CELG) (americanbankingnews.com)
- ACETO Corporation Schedules Second Quarter Fiscal 2018 Financial Results News Release and Conference Call (finance.yahoo.com)
- Cellectar Biosciences (CLRB) versus Aceto (ACET) Head-To-Head Review (americanbankingnews.com)
- Acetone Markets in China 2007-2027 – Research and Markets (markets.financialcontent.com)
Aceto (NASDAQ ACET) opened at $11.16 on Friday. The firm has a market cap of $345.36, a PE ratio of 53.14, a PEG ratio of 1.03 and a beta of 1.38. Aceto has a 1-year low of $8.29 and a 1-year high of $20.00. The company has a current ratio of 2.06, a quick ratio of 1.46 and a debt-to-equity ratio of 0.77.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Monday, December 18th were given a $0.065 dividend. This represents a $0.26 annualized dividend and a yield of 2.33%. The ex-dividend date of this dividend was Friday, December 15th. Aceto’s dividend payout ratio (DPR) is 123.81%.
ACET has been the topic of several recent research reports. Canaccord Genuity set a $15.00 price objective on shares of Aceto and gave the company a “buy” rating in a research note on Monday, October 30th. Zacks Investment Research raised shares of Aceto from a “strong sell” rating to a “hold” rating in a research note on Monday, October 30th. BidaskClub cut shares of Aceto from a “sell” rating to a “strong sell” rating in a research note on Friday, December 15th. Finally, ValuEngine cut shares of Aceto from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $15.00.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Aceto (ACET) Stock Price” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2018/01/20/aceto-acet-given-media-sentiment-rating-of-0-21.html.
Aceto Company Profile
Aceto Corporation (Aceto) is engaged in the marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals inclusive of agricultural intermediates and agricultural protection products.
Receive News & Ratings for Aceto Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aceto and related companies with MarketBeat.com's FREE daily email newsletter.